Preventing Bone Loss During Androgen Deprivation Therapy for Prostate Cancer: Early Experience with Neridronate
|
|
- Isaac Brown
- 5 years ago
- Views:
Transcription
1 European Urology European Urology 47 (2005) Preventing Bone Loss During Androgen Deprivation Therapy for Prostate Cancer: Early Experience with Neridronate Carlo Magno a, *, Giuseppina Anastasi a, Nunziata Morabito b, Agostino Gaudio b, Domenica Maisano b, Fabio Franchina b, Alessandro Galì a, Nicola Frisina b, Darwin Melloni a a Department of Urology, University of Messina, Via Garibaldi 118, 98122, Messina, Italy b Department of Internal Medicine, University of Messina, Messina, Italy Accepted 18 January 2005 Available online 30 January 2005 Abstract Objective: Androgen-deprivation therapy (ADT) is the usual treatment for locally advanced or metastatic prostate cancer. Osteoporosis is a common complication of ADT. The aim of our study was to evaluate the efficacy of neridronate, a relatively new bisphosphonate to prevent bone loss during androgen ablation. Methods: Sixty patients with prostate cancer and osteoporosis were enrolled and randomly assigned to 2 different treatment regimes: group A (30 patients) treated with maximum androgenic blockage (MAB), and group B (30 patients) treated with bicalutamide 150 mg. Each group was divided in 2 subgroups A1 A2 and B1 B2. All patients received calcium and cholecalciferol supplements (500 mg of elemental calcium and 400 IU cholecalciferol) daily. The A2 and B2 subgroups were also treated with neridronate (25 mg intramuscular monthly). Lumbar and femoral bone mineral density (BMD) was evaluated by dualenergy X-ray absorptiometry (DXA), both at baseline and after one year of treatment. Deoxypyridinoline (DPD) and bone-alkaline phosphatase (B-ALP) were determined at the beginning, midstudy and at the end. Results: Patients treated only with calcium and cholecalciferol (A1, B1 subgroups) showed a marked bone loss after 6, and 12 months, with increased levels of DPD and BALP, compared to baseline values. Patients treated with neridronate (A2 et B2 subgroups) showed unchanged levels of these markers. After one year of treatment, lumbar and total hip BMD decreased significantly in patients treated only with calcium and cholecalciferol (A1 subgroup: 4.9% and 1.9% respectively). BMD did not change significantly at any site in patients treated also with neridronate (A2 subgroup: +1% and +0.8% respectively). Lumbar and total hip BMD did not change significantly ( 1.5% and 1% respectively) in B1 subgroup. In B2 subgroup an important increase in lumbar spine and the total hip BMD was shown (+2.5% and 1.6% respectively). No relevant side effects were recorded during our study. Conclusion: In conclusion, neridronate is an effective and safe treatment in preventing bone loss in men receiving ADT for prostate cancer. # 2005 Elsevier B.V. All rights reserved. Keywords: Androgen deprivation therapy; Neridronate; Bisphosphonates; Osteoporosis; Prostate cancer 1.Introduction * Corresponding author. address: carlo.magno@tin.it (C. Magno). Androgen deprivation therapy is standard treatment for locally advanced or metastatic prostate cancer. This is readily achieved through the use of GnRH agonists /$ see front matter # 2005 Elsevier B.V. All rights reserved. doi: /j.eururo
2 576 C. Magno et al. / European Urology 47 (2005) depot, which provides a reliable means of medical castration [1]. Early primary androgen deprivation therapy (ADT) improves survival in men with locally advanced, non metastatic prostate cancer [2] who assume therapy for years. Large population studies show at long follow-up some of the complications of ADT treatment. As a matter of fact such therapy decreases BMD [3,4] and increases the risk of fracture [5,6]. This risk increases with the duration of treatment, so osteoporosis is an important complication of androgen-deprivation therapy [7]. Recent reports [8 10] have shown a high prevalence of pre-existing osteopenia and osteoporosis in men with prostate cancer, with a consistent risk of further bone loss during ADT. ADT has other adverse effects, including decrease in lean body mass and muscle size [8,11,12] that may result in frailty and increase risk of falling in older men. It seems reasonable to perform a bone densitometry before ADT because it could detect patients at high risk of developing osteoporosis [13]. Bicalutamide, a non steroidal antiandrogen, preserves BMD compared with castration, because it has no influence on levels of testosterone [14] There is not enough data concerning the treatment or prevention of osteoporosis in men with prostate cancer and many recommendations are based on studies of postmenopausal osteoporosis. Lifestyle modification including smoking cessation, moderation in alcohol consumption, regular exercise, supplemental calcium and vitamin D should be encouraged. Recent studies have evaluated the efficacy of bisphosphonates, such as pamidronate [15] and zoledronate [16,17], to prevent bone loss during androgen deprivation therapy. Men with osteoporosis before androgen deprivation or who develop it during treatment and/or experiencing adverse skeletal events may require bisphosphonates. Although alendronate, is the only bisphosphonate approved for treatment of osteoporosis [18], it has not been evaluated in men receiving ADT. Neridronate (6-amino-1-hydroxyexilidene-1,1-bisphosphonate) is a nitrogen containing bisphosphonate, structurally similar to alendronate and pamidronate, that potently inhibits osteoclast-mediated bone resorption, which has been employed, for treatment of Paget s disease [19 21] and hypercalcemia associated with cancer [22]. In addition, intravenous neridronate increases BMD in women with postmenopausal osteoporosis [23] and in patients with osteogenesis imperfecta [24]. At present, there are no controlled studies with neridronate on prevention or treatment of osteoporosis in men receiving ADT. In this study we evaluated whether intramuscular neridronate prevents bone loss in men undergoing androgen deprivation for prostate cancer. 2.Methods 2.1. Patients We studied 60 osteoporotic patients with locally advanced prostate cancer (T2 4 NX M0). Mean age was 73, 4 years (range 68 80). None of them had undergone surgery, chemotherapy or radiotherapy. Patients with Paget s disease, hyperthyroidism, Cushing s disease, hyperparathyroidism, hyperprolactinemia, chronic liver disease, or chronic renal insufficiency, previous treatment with drugs interfering with bone metabolism (androgens, glucocorticoids, bisphosphonates, calcitonin, or suppressive doses of thyroxine) were excluded. Patients were randomly assigned to two different treatment regimes: group A (30 patients) was treated with maximum androgenic blockage (triptoreline depot and bicatulamide, 50 mg daily) and group B (30 patients) with bicalutamide (150 mg daily). Each group was divided in two subgroups: A1 A2 and B1 B2. The A1 and B1 subgroups (30 patients, mean age yr, BMI kg/m 2 ) were both treated with a daily calcium and cholecalciferol supplement (500 mg of elemental calcium and 400 IU cholecalciferol). The A2 and B2 subgroups (30 patients, mean age yr, BMI kg/m 2 ) all received in addition to the calcium and cholecalciferol supplement, 25 mg of neridronate (Nerixia; Abiogen Pharma SpA, Pisa, Italy) given intramuscularly every month. Treatment lasted 1 year. Patients and investigators knew the treatment. The study was performed according to the principles of the Declaration of Helsinki, and an informed consent was obtained in every case Measurements of bone mineral density BMD was measured in all patients by a DXA densitometer (HOLOGIC QDR 4500 W), at base line and after 12 months, at the lumbar spine (L2 to L4) in A-P projection, at total hip and femoral neck. The instrument was calibrated on a daily basis according to the manufacturer s instructions. Reproducibility was calculated as a coefficient of variation (CV) obtained by weekly measurements of a standard phantom on the instrument and by repeated measurements obtained on three patients of different ages. The CV of the instrument that we used was 0.5% with standard phantom; in vivo we calculated a CV of 1.1% for the lumbar spine, 1.2% for total hip and 1.5% for neck. BMD data were expressed as grams per square centimetre Measurements of biochemical values At base-line after 6 and 12 months, fasting blood samples were taken for measurement of serum calcium (Ca, normal range mg/dl), phosphorus (P, normal range mg/dl), parathyroid hormone (PTH, normal range pg/ml), bone-alkaline phosphatase (B-ALP, normal range IU/L), 25-hydroxyvitamin D (25-OHD, normal range ng/ml), 17-beta estradiol (E2, normal range pg/ml), testosterone (T, normal range ng/dl). A 2-h fasting morning urine sample was collected at the same time for measurements of calcium (<0.525 mmol), creatinine ( mmol), and deoxypyridinoline (DPD, normal range 3 21 pmol/mmol urinary creatinine). Ca and P were determined by automatic routine procedures. PTH, E2, T and B-ALP were measured by enzyme immunoassays. DPD and 25-OHD were determined by HPLC Statistical analysis Statistical analyses were performed using StatSoft software (release 4.5). All values were expressed as mean S.D. The
3 C. Magno et al. / European Urology 47 (2005) significance of percent changes in biochemical parameters and in BMD from baseline was evaluated by Student s t-test for paired observation. The comparison of changes between groups was evaluated by analysis of variance (ANOVA) for repeated measure and then by Student s t-test for unpaired observation. All p values are two-sided, and values of less than 0.05 were considered to indicate statistical significance. 3.Results The biochemical parameters of all patients are shown in Table 1. At the beginning of the study, there were no significant differences between the treatment groups. Due to ADT, the serum concentrations of T and E2 decreased significantly in A group (p < for each comparison with baseline value). In particular serum concentrations of testosterone at 6, and 12 months in all patients were in the range of those for castrated men (<50 ng/dl). Patients treated with bicalutamide had no change of testosterone plasma levels while 17-beta-estradiol increased significantly (p < for each comparison with the baseline value). During the study period, there were no significant changes in serum Ca, P, PTH and 25-OHD concentrations in the four groups. BMI increased but not significantly during the study period in both groups of patients (data not shown) Biochemical bone markers During treatment period, DPD levels significantly increased in A1 group from baseline after 6 and 12 months and were not significantly modified in A2 subgroup. Observed changes in A1 subgroup were also statistically significant with respect to the A2 subgroup. DPD levels had no significant changes in B1 subgroup from baseline after 6, and 12 months and Table 1 Biochemical parameters at the beginning of the study, at 6 and at 12 months Length of treatment (months) Group A1 (MAB) Calcium and cholecalciferol Group A2 (MAB) Calcium and cholecalciferol plus Neridronate Group B1 (Bicalutamide) Calcium and cholecalciferol Group B2 (Bicalutamide) Calcium and cholecalciferol plus Neridronate Ca (mg/dl) P (mg/dl) PTH (pg/ml) OHD (ng/ml) T (ng/dl) a 33 4 a a 36 5 a E2 (pg/ml) a 7 3 a a 6 4 a DPD (pmol/mmol urinary creatinine) a b a,c a b a,c B-ALP (IU/L) a b a,c a b a,c Data are expressed as mean S.D. a Significant comparison with basal values (p < 0.05). b Significant comparison between group A1 and A2 (p < 0.05). c Significant comparison between group B1 and B2 (p < 0.05).
4 578 C. Magno et al. / European Urology 47 (2005) were significantly decreased in B2 subgroup. The changes in B1 subgroup were statistically significant towards the B2 subgroup. Changes in B-ALP levels were similar to those recorded for pyridinium crosslinks. In fact, in A1 subgroup, B-ALP increased from baseline at 6 and 12 months, whereas in A2 subgroup it was substantially unmodified from baseline. These changes in A1 subgroup were also statistically significant with respect to the A2 subgroup. In B1 subgroup, B-ALP showed no significant changes from baseline at 6, and 12 months, whereas in B2 subgroup it was significantly decreased from baseline at 6, and 12 months. These changes in B1 subgroup were also statistically significant with respect to the B2 subgroup. (Fig. 1) Bone mineral density All patients showed a T-score less than 2.5 S.D. at baseline. In A1 subgroup, after 12 months, BMD significantly decreased from baseline at the lumbar spine ( %, p = 0.002) and total hip ( %, p = 0.04). BMD did not significantly change at lumbar spine (p = ns), or at total hip (p = ns) from baseline for patients treated with neridronate (A2 subgroup). Changes in A1 subgroup, at lumbar spine and total hip, were also statistically significant with Fig. 2. Changes in Bone Mineral Density at 12 months of therapy in patients no treated (A1, B1) or treated (A2, B2) with neridronate. #p < 0.05 for comparisons with basal values. respect to the A2 subgroup (p < 0.05). In B1 subgroup, after 12 months, BMD slightly decreased not reaching significance at lumbar spine ( %, p = ns) and total hip ( %, p = ns). BMD significantly changed at lumbar spine ( %, p < 0.05), or at total hip ( %, p < 0.05) in patients treated with neridronate (B2 subgroup). Changes in B1 subgroup, BMD at lumbar spine and total hip, were also statistically significant with respect to B2 subgroup (p < 0.05). In A1 subgroup, after 12 months, BMD decreased both at lumbar spine and total hip, lower than in B1 subgroup (p < 0.001). In B2 subgroup, treated with bicalutamide, calcium, cholecalciferol and neridronate, BMD significantly increased with respect to A2 subgroup (p < 0.001). (Fig. 2) Adverse events No relevant side effects due to neridronate were recorded during our study. A transient flu-like syndrome, not requiring treatment, was observed in 3/30 patients (10%) treated with neridronate after the first administration. 4.Discussion Fig. 1. Mean changes in urinary excretion of deoxypyridinoline and serum concentrations of bone alkaline phosphatase in patients no treated (A1, B1) or treated (A2, B2) with neridronate. Measurements of the biochemical bone markers (DPD and B-ALP) at baseline, at 6 months, and at 12 months. Bone loss commonly occurs in men with prostate cancer treated with ADT, and its rate seems to exceed that associated with menopause in women. In patients treated with ADT, markers of bone turnover (DPD and B-ALP) significantly increased and total hip and vertebral BMD markedly decreased [25,26]. Bisphosphonates currently seem to be the most promising therapy in this type of osteoporosis with enhanced turnover. They represent a logical therapy in men who have low BMD at baseline or who develop bone loss during the course of therapy. Two recent papers review the role of
5 C. Magno et al. / European Urology 47 (2005) bisphosphonates: Saad et al. state that bisphosphonates act against osteoclasts which affect bone integrity [27], and Bae et al. recommend that bisphosphonate treatment is initiated in men who have osteopenia or osteoporosis [28] The present study shows that neridronate prevents bone loss in men undergoing treatment for prostate cancer with ADT. The markers of bone resorption and bone formation that increased in the group of patients treated with calcium and vitamin D alone, did not show any significant elevation in patients receiving neridronate plus calcium and vitamin D, during the study period remaining substantially stable. This data is different from data reported by Smith et al. [15] who evaluated the effect of two years of treatment with pamidronate in patients in ADT for prostate cancer. Serum B-ALP and osteocalcin concentrations initially decreased in patients treated with pamidronate then approached or returned to baseline levels by 48 weeks, whereas bone resorption markers, urinary DPD and N-Telopeptide initially decreased and then increased exceeding the baseline value after 12 weeks. Concerning BMD in our patients, neridronate was able to prevent bone loss due to ADT, not modifying BMD at any levels. Since low BMD is a determining factor for fracture risk [29], these findings suggest that neridronate may reduce this risk in subjects receiving ADT for treatment of prostate cancer. This data is in accordance with a previous report by Smith et al. [15], who demonstrated that pamidronate similarly prevents bone loss in androgen deprivated patients affected by prostate cancer. ADT can modify body composition. In fact, low levels of testosterone are associated with increase in total body fat and loss of lean body mass. In our study, we did not evaluate body composition, but only BMI. It increased but not significantly in both groups of patients. In patients over 65 years of age with low-normal serum testosterone concentrations, testosterone treatment as compared with placebo did not increase BMD in lumbar spine [30,31]. In uncontrolled studies of patients with congenital or acquired primary or secondary hypogonadism, testosterone-replacement therapy increased BMD [31,32]. To our knowledge, there is little data about prevention and/or treatment of osteoporosis in androgen deprivated patients affected by prostate cancer. Recent studies demonstrate the efficacy of several bisphosphonates such as pamidronate and zoledronic acid, in this condition. Smith et al. [15] reported prevention of bone loss with pamidronate in patients treated by LH-RH analogues for prostatic cancer. Recently, a random placebo controlled study showed that zoledronic acid, a third-generation bisphosphonate indicated for treatment of bone metastases from multiple myeloma and solid tumours, at the dosage of 4 mg intravenously every 3 months, not only prevented bone loss but also increased BMD during ADT for prostate carcinoma [16,17]. Alendronate is the only bisphosphonate approved for treatment of male osteoporosis. Oral alendronate increases BMD and helps to decrease vertebral fracture in subjects with osteoporosis and normal or near normal serum testosterone concentrations [18]. The efficacy of alendronate in hypogonadal men is not known. Neridronate, a bisphosphonate structurally similar to alendronate and pamidronate, has been used successfully in various clinical conditions. Quarterly and intravenously administered, it significantly increased BMD and lowered risk of clinical fracture in adults with osteogenesis imperfecta [23]. Treatment of postmenopausal osteoporosis with 50 mg intravenous neridronate bimonthly results in a clinically relevant increase in BMD, one amongst the largest so far observed using any other bisphosphonate [22]. Moreover, neridronate was effective in decreasing bone turnover parameters in Paget s disease [18 20]. For the first time, our study provides evidence that neridronate Intramuscularly, monthly given, is effective in preventing bone loss in castrated men for prostate cancer. Furthermore, treatment with neridronate was well-tolerated as confirmed by low frequency (5%) and no severity of adverse effects recorded. Our study it is somewhat limited in statistical power because of the small sample size. Larger, additional, prospective studies are needed to evaluate the longterm effects of this bisphosphonate for fracture risk and disease-related outcomes. Finally, as increased bone turnover and low bone density are associated with higher risk of osteoporotic fractures, we suggest that during ADT treatment patients should receive bisphosphonates, like neridronate, to prevent further bone loss and fractures. 5.Conclusion Even if this study is based on a relatively small series of patients, we can conclude that neridronate is an effective treatment in preventing bone loss in men receiving ADT for prostate cancer. We can also confirm in our investigation that bicatulamide does not cause bone loss during prolonged therapy in prostate cancer patients. Neridronate may be administered in patients treated by bicatulamide only in case of evidence of osteoporosis.
6 580 C. Magno et al. / European Urology 47 (2005) References [1] Garnick M, The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984;311: [2] The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997;79: [3] Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000;163: [4] Smith MR. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology 2002;60: [5] Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 2000;86: [6] Melton III LJ, Alothman KI, Kosla S, Achenbach SJ, Oberg AL, Zinke H. Fracture risk following bilateral orchiectomy. J Urol 2003;169: [7] Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001;166: [8] Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002;167: [9] Hussain SA, Weston R, Stephenson RN, George E, Parr NJ. Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int 2003;92: [10] Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 2001;9: [11] Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87: [12] Chen Z, Maricic M, Nguyen P, Ahmann FR, BruhnBruce R, Dalkin L. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer 2002;95: [13] Morote J, Martinez E, Trilla E, Esquena S, Abascal JM, Encabo G, et al. Osteoporosis during continuous androgen deprivation: Influence of the modality and length of treatment. Eur Urol 2003; 44: [14] Tyrrell CD, Blacke GM, Iversen P, Kaisary AV, Melezinek I. The non steroidal antiandrogen, bicalutamide (casodex), may preserve bone mineral density as compared with castration: results of a preliminary study. World J Urol 2003;21: [15] Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, et al. Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N Engl J Med 2001;345: [16] Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non metastatic prostate cancer. J Urol 2003;169: [17] Guise TA, Eastham JA. Cancer treatment induce bone loss in prostate cancer: pathophysiology preclinical findings and treatment with zoledronic acid. Eur Urol (Suppl 3):2004; [18] Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343: [19] Delmas PD, Chapuy MC, Edouard C, Meunier PJ. Beneficial effects of aminohexane bisphosphonate in patients with Paget s disease of bone resistant to sodium etidronate. Am J Med 1987;83: [20] Filipponi P, Cristallini S, Policani G, Casciari C, Gregorio F. Paget s disease of bone: benefits of neridronate as a first treatment and in cases of relapse after clodronate. Bone 1998;23: [21] Adami S, Bevilacqua M, Broggini M, Filipponi P, Ortolani S, Palummeri E, et al. Short-term intravenous therapy with Neridronate in Paget s disease. Clin Exp Rheumatol 2002;20:55 8. [22] O Rourke NP, McCloskey EV, Rosini S, Coleman RE, Kanis JA. Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate). Br J Cancer 1994;69: [23] Braga V, Gatti D, Colapietro F, Battaglia E, Rigetti D, Prizzi R, et al. Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis. Bone 2003;33: [24] Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 2003;18: [25] Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002;87: [26] Preston DM, Torrens JI, Harding P, Howard RS, Duncan WE, McLeod DG. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis 2002;5: [27] Saad F, Schulman CC. Role of Bisphosphonates in Prostate Cancer. Eur Urol 2004;45: [28] Bae DC, Stein BS. The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate. J Urol 2004 Dec;172(6 Pt 1): [29] Cummings SR, Black DM, Nevitt MC, Browner WS, Cauley JA, Genant HK, et al. Appendicular bone density and age predict hip fracture in women. JAMA 1990;263: [30] Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84: [31] Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996;81: [32] Finkelstein JS, Klibanski A, Neer RM, Doppelt SH, Rosenthal DI, Segre GV, et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989;69: Editorial Comment Fred Saad, Montreal, Canada fredsaad@videotron.ca Bone health and prostate cancer: A new challenge for urologists Bone health related to prostate cancer has become an important area of research. Urologists and other specialists treating patients with prostate cancer need to be aware of the potential bone complications that can arise not only from bone metastases but
7 C. Magno et al. / European Urology 47 (2005) also from the accelerated bone loss that may occur in patients treated with androgen deprivation. This is going to be a new challenge for urologists. They will have to become familiar with things like bone mineral density, words like osteopenia and osteoporosis and drugs that may prevent or correct bone loss such as bisphosphonates. Urologists need to be actively involved in this area if they want to continue to play a lead role in the management of prostate cancer. Bisphosphonates such as pamidronate and zoledronic acid have proven to be effective in ADT induced bone loss and other agents are presently being studied in large randomised trials. The authors of this paper have conducted a small study using a new monthly intra muscular bisphosphonate, neridronate, and have shown it to be effective in preventing bone loss in men on ADT. If the results are similar in larger studies this will become another interesting alternative for patients at risk of osteoporosis. With all this new information it will be essential, in the near future, to develop some consensus guidelines. This will eventually help urologists to better evaluate, follow and treat patients on ADT with regards to the question of bone health.
Breast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationClinical Study Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog
Hindawi Publishing Corporation Prostate Cancer Volume 2, Article ID 7664, 7 pages doi:.55/2/7664 Clinical Study Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing
More informationThe relationship between daily calcium intake and bone mineral density in men with prostate cancer
Original Article DAILY CALCIUM INTAKE AND BONE MINERAL DENSITY IN PROSTATE CANCER PLANAS ET AL. The relationship between daily calcium intake and bone mineral density in men with prostate cancer Jacques
More informationThe New England Journal of Medicine PAMIDRONATE TO PREVENT BONE LOSS DURING ANDROGEN-DEPRIVATION THERAPY FOR PROSTATE CANCER.
PAMIDRONATE TO PREVENT BONE LOSS DURING ANDROGEN-DEPRIVATION THERAPY FOR PROSTATE CANCER MATTHEW R. SMITH, M.D., PH.D., FRANCIS J. MCGOVERN, M.D., ANTHONY L. ZIETMAN, M.D., MARY ANNE FALLON, L.P.N., DOUGLAS
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationOral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis
Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis Miriam Silverberg A. Study Purpose and Rationale More than 70% of fractures in people after the age of
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationOsteoporosis in Men. Until recently, the diagnosis of osteoporosis. A New Type of Patient. Al s case. How is the diagnosis made?
A New Type of Patient Rafat Faraawi, MD, FRCP(C), FACP Until recently, the diagnosis of osteoporosis in men was uncommon and, when present, it was typically described as a consequence of secondary causes.
More informationStudy of secondary causes of male osteoporosis
Study of secondary causes of male osteoporosis Suárez, S.M., Giunta J., Meneses G., Costanzo P.R., Knoblovits P. Department of Endocrinology, Metabolism and Nuclear Medicine of Hospital Italiano of Buenos
More informationHanan Shawky 1 and Tarek Gamil 2.
Relationship of Combined Androgen Deprivation Therapy and Bone Turnover Markers with Bone Mineral Density, Lean Body Mass and Fat Content in Patients with Non- Metastatic Prostate Cancer Hanan Shawky 1
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationOSTEOPOROSIS MANAGEMENT AND INVESTIGATION. David A. Hanley, MD, FRCPC
OSTEOPOROSIS MANAGEMENT AND INVESTIGATION David A. Hanley, MD, FRCPC There is a huge care gap in the management of osteoporosis in this country. As yet unpublished findings from the Canadian Multicentre
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationEuropean Journal of Endocrinology (1997) ISSN
European Journal of Endocrinology (1997) 137 167 171 ISSN 0804-4643 Change in C-terminal cross-linking domain of type I collagen in urine, a new marker of bone resorption, during and after gonadotropin-releasing
More informationReview Article RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis
SAGE-Hindawi Access to Research Osteoporosis Volume 2011, Article ID 941310, 6 pages doi:10.4061/2011/941310 Review Article RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationQCT BMD Imaging vs DEXA BMD Imaging
QCT BMD Imaging vs DEXA BMD Imaging by Charles (Chuck) Maack Prostate Cancer Advocate/Activist Disclaimer: Please recognize that I am not a Medical Doctor. I have been an avid student researching and studying
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationToremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Matthew R. Smith,*,, Ronald A. Morton,* K. Gary Barnette,* Paul R. Sieber, S. Bruce Malkowicz, Domingo
More informationIntegrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options
Paris, November 1st 2016 Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options René Rizzoli MD International Osteoporosis Foundation and Division of Bone
More informationBisphosphonates in the Management of. Myeloma Bone Disease
Bisphosphonates in the Management of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Myeloma Bone Disease Myeloma cells
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationDepartment of Urology, Kitasato University School of Medicine 2
Original Contribution Kitasato Med J 2012; 42: 51-56 The impact of urinary cross-linked N-telopeptide of type I collagen in patients with prostate cancer receiving long-term risedronate treatment and androgen-deprivation
More informationVivek K. Wadhwa, Robin Weston and Nigel J. Parr Department of Urology, Wirral University Teaching Hospitals, Wirral, UK
21 THE AUTHORS; 21 Urological Oncology BICALUTAMIDE MONOTHERAPY IN PROSTATE CANCER WADHWA ET AL. BJUI Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related
More informationBody composition changes during androgen deprivation therapy for prostate cancer: A 2-year prospective study
Critical Reviews in Oncology/Hematology 68 (2008) 172 177 Body composition changes during androgen deprivation therapy for prostate cancer: A 2-year prospective study Gijsberta J. van Londen a,, Matthew
More informationOsteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK
Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into
More informationSkeletal complications of ADT: disease burden and treatment options
(2012) 14, 670 675 ß 2012 AJA, SIMM & SJTU. All rights reserved 1008-682X/12 $32.00 www.nature.com/aja REVIEW Skeletal complications of ADT: disease burden and treatment options Jacques Planas Morin and
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationHOW I DO IT. Introduction. BARKIN J. How I Do It: Managing bone health in patients with prostate cancer. Can J Urol 2014;21(4):
HOW I DO IT How I Do It: Managing bone health in patients with prostate cancer Jack Barkin, MD Department of Surgery, University of Toronto, Humber River Hospital, Toronto, Ontario, Canada BARKIN J. How
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationMetastatic prostate carcinoma. Lee Say Bob July 2017
Metastatic prostate carcinoma Lee Say Bob July 2017 Scenario A 58 year old gentleman presents with PSA 200 ng/ml with hard prostate and bone mets. LUTS but upper tracts are normal with normal RP. history
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationAETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents
AETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents Injectable Osteoporosis Agents Forteo (teriparatide); zoledronic acid Prolia (denosumab)] Authorization guidelines For
More information[If no, skip to question 10.] Y N. 2. Does the member have a diagnosis of Paget s disease of bone? Y N. [If no, skip to question 4.
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Zoledronic Acid (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationDiagnosis and Treatment of Osteoporosis. Department of Endocrinology and Metabolism Ajou University School of Medicine.
Diagnosis and Treatment of Osteoporosis Department of Endocrinology and Metabolism Ajou University School of Medicine Yoon-Sok CHUNG WCIM, COEX, Seoul, 27Oct2014 Case 1 71-year old woman Back pain Emergency
More informationNeed for Measurement of Bone Mineral Density in Patients of Prostate Cancer Before and After Orchidectomy: Role of Quantitative Computer Tomography
Original Article Need for Measurement of Bone Mineral Density in Patients of Prostate Cancer Before and After Orchidectomy: Role of Quantitative Computer Tomography MM Agarwal*, AK Mandal**, N Khandelwal**,
More informationRESEARCH ARTICLE. Hui Ding 1, Li Yang 1, Wan Du 2, Yang Teng 3, Sheng-Jun Fu 1, Yan Tao 1, Jian-Zhong Lu 1, Zhi-Ping Wang 1,4 * Abstract.
DOI:http://dx.doi.org/10.7314/APJCP.2013.14.5.3337 RESEARCH ARTICLE Bisphosphonates for Osteoporosis in Nonmetastatic Prostate Cancer Patients Receiving Androgen-deprivation Therapy: A Systematic Review
More informationAndrogen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Celestia S Higano SUMMARY Androgen deprivation therapy (ADT) alone or in combination with
More informationAromatase Inhibitors & Osteoporosis
Aromatase Inhibitors & Osteoporosis Miss Sarah Horn Consultant Oncoplastic Breast Surgeon April 2018 Aims Role of Aromatase Inhibitors (AI) in breast cancer treatment AI s effects on bone health Bone health
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More information3. Has bone specific alkaline phosphatase level increased OR does the member have symptoms related to active Paget s?
Pharmacy Prior Authorization AETA BETTER HEALTH VIRGIIA CCC PLUS and MEDALLIO/FAMIS 4.0 Zoledronic Acid (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationOverview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence
Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling
More informationPostmenopausal osteoporosis is a systemic
OSTEOPOROSIS: HARD FACTS ABOUT BONES Steven T. Harris, MD, FACP* ABSTRACT As a consequence of the aging process, osteoporosis affects all men and women. Agerelated loss of bone mass leads to skeletal fragility
More informationDENOSUMAB (PROLIA & XGEVA )
DENOSUMAB (PROLIA & XGEVA ) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 306.3 T2 Effective Date: July 2, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Reclast, Zometa) Reference Number: CP.PHAR.59 Effective Date: 03.11 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationdenosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationBased on review of available data, the Company may consider the use of denosumab (Prolia) for the
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationO. Bruyère M. Fossi B. Zegels L. Leonori M. Hiligsmann A. Neuprez J.-Y. Reginster
DOI 10.1007/s00296-012-2460-y ORIGINAL ARTICLE Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security
More informationPractical Management Of Osteoporosis
Practical Management Of Osteoporosis CONFERENCE 2012 Education Centre, Bournemouth.19 November The following companies have given funding towards the cost of this meeting but have no input into the agenda
More informationName of Policy: Boniva (Ibandronate Sodium) Infusion
Name of Policy: Boniva (Ibandronate Sodium) Infusion Policy #: 266 Latest Review Date: April 2010 Category: Pharmacology Policy Grade: Active Policy but no longer scheduled for regular literature reviews
More informationEfficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
Rheumatol Int (2006) 26: 427 431 DOI 10.1007/s00296-005-0004-4 ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis:
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationTEAM SCIENCE AT A PROGRAMMATIC LEVEL. Sundeep Khosla, M.D. Mayo Clinic College of Medicine
TEAM SCIENCE AT A PROGRAMMATIC LEVEL Sundeep Khosla, M.D. Mayo Clinic College of Medicine APPROACH TO TRANSLATIONAL RESEARCH IN OSTEOPOROSIS Epidemiological Studies Clinical Investigation Mouse and Cellular
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationDisclosure and Conflicts of Interest Steven T Harris MD Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis
Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis Steven T Harris MD FACP Clinical Professor of Medicine University of California, San Francisco Disclosure and Conflicts of Interest
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationOriginal Article Fasting Plasma Glucose Levels Are Related to Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism
www.ijcem.com/ijcem807001 Original Article Fasting Plasma Glucose Levels Are Related to Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism Itoko Hisa 1, Hiroshi Kaji 1, Yoshifumi
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationCorrelation between Thyroid Function and Bone Mineral Density in Elderly People
IBBJ Spring 2016, Vol 2, No 2 Original Article Correlation between Thyroid Function and Bone Mineral Density in Elderly People Ali Mirzapour 1, Fatemeh Shahnavazi 2, Ahmad Karkhah 3, Seyed Reza Hosseini
More informationOSTEOPOROSIS AND WHAT TO DO AFTER A VERTEBRAL FRACTURE. Lydia Au Geriatrics Ng Teng Fong Hospital
OSTEOPOROSIS AND WHAT TO DO AFTER A VERTEBRAL FRACTURE Lydia Au Geriatrics Ng Teng Fong Hospital LET S START WITH WHAT YOU WANT TO KNOW AND DO WITH A VERT FRACTURE Vertebral fractures Most common (550K
More informationOsteoporosis in Men Professor Peter R Ebeling
Osteoporosis in Men MD FRACP Head, Department of Medicine, School for Clinical Sciences Monash Health Translation Precinct Monash University, Clayton, Victoria 1 MonashHealth Potential Conflicts Departmental
More informationParathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary
Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationKristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review
Kristen M. Nebel, DO PENN/ LGHP Geriatrics 10/3/17 Temple Family Medicine Review OBJECTIVES Define Revised 2017 American College of Physician Recommendations Screening, Prevention and Treatment Application
More informationBreast Cancer and Bone Health. Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield
Breast Cancer and Bone Health Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield Breast Cancer and Bone Health Normal Bone Health Impact of Cancer Therapies on Bone Health Therapeutic
More informationChanges in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer
Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer S Egawa 1 *, H Okusa 1, K Matsumoto 1, K Suyama 1 & S Baba 1 1 Department
More informationCalcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD
Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationThe Role of the Laboratory in Metabolic Bone Disease
The Role of the Laboratory in Metabolic Bone Disease Howard Morris PhD, FAACB, FFSc(RCPA) President, IFCC Professor of Medical Sciences, University of South Australia, Clinical Scientist, SA Pathology
More informationJOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014
HYPOVITAMINOSIS D IN INDIAN FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS DR. SHAH WALIULLAH 1 DR. VINEET SHARMA 2 DR. R N SRIVASTAVA 3 DR. YASHODHARA PRADEEP 4 DR. A A MAHDI 5 DR. SANTOSH KUMAR 6 1 Research
More informationBone Densitometry Pathway
Bone Densitometry Pathway The goal of the Bone Densitometry pathway is to manage our diagnosed osteopenic and osteoporotic patients, educate and monitor the patient population at risk for bone density
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationAN APPROACH TO THE PATIENT WITH OSTEOPOROSIS. Malik Mumtaz
Malaysian Journal of Medical Sciences, Vol. 8, No. 1, Januari 2001 (11-19) BRIEF ARTICLE Department of Medicine School of Medical Sciences, Universiti Sains Malaysia 16150 Kubang Kerian, Kelantan, Malaysia
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Biochemical Markers of Bone Turnover: Definitions and Recommendations for Monitoring Therapy Learning Objectives for Biochemical
More informationCa, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary
Ca, Mg metabolism, bone diseases Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Calcium homeostasis Ca 1000g in adults 99% in bones (extracellular with Mg, P) Plasma/intracellular
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationOsteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide was developed to assist Primary Care physicians
More informationThis house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against
This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against Juliet Compston Professor of Bone Medicine University of Cambridge School of Clinical
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. INJECTABLE OSTEOPOSIS AGENTS SUBJECT Pharmacologic Agents: Bisphosphonates: Boniva IV (ibandronate) Reclast (zoledronic
More informationAn audit of osteoporotic patients in an Australian general practice
professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to
More information9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy
The Impact of Dietary Protein on the Musculoskeletal System Outline A. The musculoskeletal system and associated disorders Jessica D Bihuniak, PhD, RD Assistant Professor of Clinical Nutrition Department
More informationSummary. Background. Diagnosis
March 2009 Management of post-menopausal osteoporosis This bulletin focuses on the pharmacological management of patients with post-menopausal osteoporosis both those with clinically evident disease (e.g.
More informationOsteoporosis - recent advances in diagnosis and treatment
Title Osteoporosis - recent advances in diagnosis and treatment Author(s) Kung, AWC Citation The 4th Medical Research Conference (MRC 1999), Hong Kong, China, 30-31 January 1999. In Hong Kong Practitioner,
More information